MetaCap

QuidelOrtho (QDEL) vs Alpha Teknova (TKNO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Alpha Teknova (TKNO) has outperformed QuidelOrtho (QDEL) over the past year, gaining 77.4% versus a loss of 65.8%. Over five years, TKNO leads with a -63.6% price change compared with -94.3% for QDEL. QuidelOrtho is the larger company by market cap ($570.9 million vs $480.0 million), about 1.2 times the size, while Alpha Teknova is growing revenue faster (+7.4% vs -1.9%).

QuidelOrtho converts more of its revenue into profit, with a net margin of -41.5% versus -42.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QDEL-65.83%TKNO+77.44%
+126%+26%-75%
Nov 21, 20251 yearNov 20, 2026
QDEL-94.54%TKNO-69.50%
+11%-45%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QDEL versus TKNO key metrics
MetricQDELTKNO
Share price$8.32$7.63
Market cap$570.86M$479.95M
1-day change-6.73%-2.30%
YTD return-70.87%+100.79%
1-year return-65.83%+77.44%
5-year return-94.25%-63.63%
Forward P/E6.32—
EPS (TTM)$-5.39$-0.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.73B$40.52M
Revenue growth (YoY)-1.89%+7.35%
Net income (latest FY)$-1.13B$-17.26M
Gross margin46.67%33.17%
Operating margin-33.67%-41.90%
Net margin-41.45%-42.59%
52-week high$35.58$9.48
52-week low$8.06$1.91
Distance from 52-week high-76.62%-19.51%
Analyst consensusholdnone
Avg. price target upside+80.29%+28.83%
Average volume2.04M437.31K
Shares outstanding68.61M62.90M
Employees6,500158
SectorHealth CareHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic SubstancesBiotechnology: In Vitro & In Vivo Diagnostic Substances

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TKNO has outperformed QDEL by 143.3 percentage points over the past year.
  • Alpha Teknova grew revenue faster in its latest fiscal year (+7.35% vs -1.89%).

About QuidelOrtho

QDEL stock →

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 6,500 employees

About Alpha Teknova

TKNO stock →

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees

QDEL vs TKNO FAQ

Which is bigger, QuidelOrtho or Alpha Teknova?

QuidelOrtho (QDEL) is larger, with a market capitalization of $570.86M compared with $479.95M for Alpha Teknova (TKNO).

Which stock has performed better over the past year, QDEL or TKNO?

TKNO returned +77.44% over the past 12 months, compared with -65.83% for QDEL (price return, excluding dividends). Past performance does not predict future results.

Are QuidelOrtho and Alpha Teknova in the same industry?

Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.

More comparisons